Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Shares Repurchased (2016)

Myriad Genetics has reported Shares Repurchased over the past 7 years, most recently at $10.3 million for Q4 2016.

  • Quarterly Shares Repurchased fell 58.63% to $10.3 million in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Mar 2019, changed N/A year-over-year, with the annual reading at $50.0 million for FY2019, N/A changed from the prior year.
  • Shares Repurchased was $10.3 million for Q4 2016 at Myriad Genetics, down from $21.3 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $102.3 million in Q3 2013 and troughed at $10.3 million in Q4 2016.
  • The 5-year median for Shares Repurchased is $44.9 million (2013), against an average of $45.6 million.
  • The largest YoY upside for Shares Repurchased was 273.36% in 2013 against a maximum downside of 64.6% in 2013.
  • A 5-year view of Shares Repurchased shows it stood at $33.7 million in 2012, then skyrocketed by 130.99% to $77.8 million in 2013, then dropped by 25.07% to $58.3 million in 2014, then crashed by 57.29% to $24.9 million in 2015, then crashed by 58.63% to $10.3 million in 2016.
  • Per Business Quant, the three most recent readings for MYGN's Shares Repurchased are $10.3 million (Q4 2016), $21.3 million (Q3 2016), and $54.7 million (Q2 2016).